Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 7/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25713050 | 0.95 | MAPK14 (0.34) | TOP1TRPV1MAPK14KDM4EMAOB | |
| SCHEMBL25713123 | 0.95 | MAPK14 (0.34) | TOP1TRPV1MAPK14KDM4EMAOB | |
| SCHEMBL24056976 | 0.94 | TOP1 (0.33) | TOP1TRPV1MAPK14ATRALDH1A1 | |
| SCHEMBL24055970 | 0.94 | TOP1 (0.33) | TOP1TRPV1MAPK14ATRALDH1A1 | |
| SCHEMBL24057457 | 0.94 | TOP1 (0.33) | TOP1TRPV1MAPK14ATRALDH1A1 | |
| SCHEMBL25713032 | 0.94 | MAPK14 (0.33) | TOP1TRPV1MAPK14KDM4EMAOB | |
| SCHEMBL25713107 | 0.94 | MAPK14 (0.33) | TOP1TRPV1MAPK14KDM4EMAOB | |
| SCHEMBL25713216 | 0.91 | KDM4E (0.42) | TOP1ATRALDH1A1HSD17B10KDM4E | |
| SCHEMBL25713098 | 0.89 | TRPV1 (0.32) | TOP1TRPV1MAPK14KDM4EMAPT | |
| SCHEMBL25713154 | 0.89 | KDM4E (0.34) | TOP1TRPV1MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157159-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230157159-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157159-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | NR0B1, AHR, ARL1 | TOP1 1473/4885TRPV1 612/4885MAPK14 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.